In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was...
Read MoreOngoing treatment(s)-Biological/Targeted therapy Posts on Medivizor
Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?
In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was associated...
Read MoreHow effective is idarubicin-substituted BEAC (IEAC) as a conditioning regimen for patients with B-cell non-Hodgkin’s lymphoma undergoing ASCT?
In a nutshell This study compared the BEAC (BCNU, etoposide, cytarabine, and cyclophosphamide) and IEAC (idarubicin, etoposide, cytarabine, and cyclophosphamide) regimens before autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (r/r) and aggressive B-cell non-Hodgkin lymphoma (NHL). The study found that IEAC regimen...
Read MoreHow the characteristics of CAR-T cell infusion products impact their effectiveness and toxicity in patients with large B cell lymphomas
In a nutshell The study evaluated how characteristics of CAR-T cell infusion (CTCI) products impact their effectiveness and toxicity in patients with large B cell lymphoma (LBCL). The authors found that diversity in molecular and cellular features of CTCI products caused variations in efficacy and toxicity after axicabtagene-ciloleucel (axi-cel;...
Read MoreEvaluating lenalidomide-rituximab treatment for follicular lymphoma
In a nutshell This study looked at the effectiveness of rituxumab (Rituxan) with lenalidomide (Revlimid) for untreated follicular lymphoma (FL). It found that this treatment was more effective than rituxumab with chemotherapy. They also found that blood tests of trace FL can predict outcomes. Some background Follicular lymphoma (FL) is a slow-growing...
Read MoreBlinatumomab for unresponsive aggressive non-Hodgkin lymphoma
In a nutshell This study looked at using both chemotherapy and blinatumomab (Blincyto) prior to stem cell transplant (SCT) for patients with relapsed or unresponsive aggressive non-Hodgkin lymphoma (NHL). It found that blinatumomab is an effective second salvage for patients who did not fully respond to chemotherapy. Some background NHL is a...
Read MoreThe impact of a pharmaceutical care program for patients with B-cell lymphoma treated with ibrutinib
In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with B-cell non-Hodgkin's lymphoma (NHL). This study concluded that the management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better tolerance than...
Read MoreManaging the side effects of ibrutinib treatment
In a nutshell This review aimed to discuss the toxicities of ibrutinib (Imbruvica) treatment and how to manage them. This review concluded that patients should be regularly monitored for toxicities and actively treated to reduce side effects and avoid disruption to treatment. Some background Ibrutinib is a type of targeted therapy known as a...
Read MoreWhich targeted therapy leads to the best quality of life for advanced FL?
In a nutshell This study looked at the quality of life for patients with advanced follicular lymphoma (FL) who were treated with obinutuzumab (Gazyva) and chemotherapy compared to those treated with rituximab (Rituxan) and chemotherapy. It found that both targeted antibody therapies improved quality of life for patients with advanced FL. Some background...
Read MoreEvaluating the risk of infection associated with ibrutinib treatment in patients with B-cell lymphoma
In a nutshell This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as lymphoma. This study concluded that ibrutinib was associated with a higher risk of infections in these patients. Some background B-cell malignancies such as non-Hodgkin lymphoma (NHL) lead to an increased risk of...
Read MoreEvaluating immune-related side effects associated with pembrolizumab.
In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...
Read MoreHow does maintenance therapy affect quality of life for patients with DLBCL?
In a nutshell This study evaluated lenalidomide (Revlimid) maintenance therapy versus placebo for patients with diffuse large B-cell lymphoma (DLBCL). The authors found that lenalidomide increased the number of side effects but did not impact health status. Some background DLBCL is an aggressive type of non-Hodgkin's lymphoma....
Read More